Infinity pharmaceuticals, inc. (INFI)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities
Net loss

-44,199

-47,057

-43,895

-19,097

-15,546

-11,253

-10,329

-30,815

-40,806

-41,830

-57,464

-69,857

88

-30,101

-46,361

15,681

-75,738

-128,376

-129,528

-68,856

-68,452

-17,416

-9,999

-147,153

-141,720

-126,780

-140,840

-88,499

-70,568

-53,964

-21,040

-51,387

-48,458

-40,042

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

329

219

112

93

138

191

231

447

1,086

1,715

2,497

3,416

3,417

3,418

3,301

2,710

2,631

2,292

1,963

1,821

1,659

1,773

1,854

1,872

1,849

1,823

1,722

1,661

1,639

1,643

1,723

1,790

1,967

2,099

0

0

0

Stock-based compensation, including 401(k) match

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,595

12,588

12,443

12,770

11,907

12,155

12,064

10,572

10,299

7,811

6,372

5,956

5,551

5,441

0

0

0

Stock-based compensation

1,810

2,133

2,537

2,966

3,248

3,448

4,165

4,896

6,048

6,972

8,788

9,990

11,806

13,714

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash royalty revenue

705

555

392

212

76

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

2,334

2,600

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash related party interest expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on long-term debt due to Purdue entities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,908

0

0

0

-

-

-

-

Non-cash interest expense on Due to Takeda amount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of loan commitment asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

647

1,681

6,219

9,157

9,649

0

0

0

-

-

-

-

-

-

-

-

1,588

0

0

0

Net amortization of premium/discount on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-737

-1,257

-1,759

-2,243

-2,400

-2,201

-2,154

-1,933

-1,754

-1,653

-1,271

-1,044

-940

-915

0

0

0

Other, net

217

216

174

83

-40

-138

-137

-143

-43

25

142

108

51

2

207

188

107

162

-240

-224

-114

-83

0

0

0

-

-

-

-132

-46

-55

-68

-65

-72

0

0

0

Changes in operating assets and liabilities:
Unbilled accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-218

0

0

0

-

-

-

-

Unbilled accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Prepaid expenses and other assets

-1,470

756

1,118

389

2,167

71

-5,952

-246

-2,570

-7,110

-5,551

-11,427

-13,541

-5,208

2,508

1,386

8,252

-933

-2,964

-2,566

-5,477

494

5,728

6,493

6,860

7,284

756

1,570

875

1,037

577

226

1,495

-356

0

0

0

Operating lease right-of-use assets

-420

-364

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued expenses and other liabilities

537

1,550

1,875

1,739

2,925

2,833

1,944

-4,091

-4,878

-17,799

-24,998

-37,937

-26,656

-15,708

-7,554

18,054

15,225

11,774

4,386

8,615

574

6,815

11,300

2,636

5,457

3,565

-930

-9,395

-9,731

-12,395

-3,601

6,851

5,354

1,359

0

0

0

Operating lease liability

92

225

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Due to Takeda

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,667

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Due to Takeda

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-18,723

-27,801

11,455

16,043

20,934

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-154,356

-50,620

-50,450

-35,868

-83,653

-213,401

59,756

61,612

117,715

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

Deferred revenue from Purdue entities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-39,941

5,205

-1,358

-4,781

0

0

0

Net cash used in operating activities

-37,632

-41,530

-16,297

-13,469

-11,134

-4,714

-19,864

-23,910

-28,791

-36,711

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-52,602

-29,124

-35,185

-33,109

0

0

0

Investing activities
Purchases of property and equipment

2,312

2,327

1,560

224

33

0

0

0

0

-

-

-

-

661

1,671

3,095

5,584

6,426

6,414

5,060

2,298

1,362

772

1,054

1,643

1,754

1,980

1,941

1,352

1,301

1,387

1,237

1,447

1,542

0

0

0

Purchases of available-for-sale securities

49,017

41,864

37,681

31,703

22,521

15,686

17,684

29,729

29,729

23,985

36,000

26,811

32,180

66,503

109,506

96,708

155,779

121,456

64,440

73,693

9,253

21,789

40,954

81,435

170,471

249,764

277,245

306,782

260,520

180,498

192,476

145,993

129,328

150,588

0

0

0

Proceeds from maturities of available-for-sale securities

47,130

31,950

17,500

11,500

22,260

28,790

29,790

29,790

12,530

19,000

27,775

50,799

99,290

93,400

109,299

124,857

86,377

89,515

96,134

64,517

115,080

141,004

178,261

245,109

251,925

251,093

213,226

166,717

132,031

113,520

100,714

118,628

116,439

137,153

0

0

0

Proceeds from sales of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,289

0

0

0

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

40,329

11,221

37,471

-74,522

-37,903

25,744

-14,236

103,529

117,853

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-4,199

-12,241

-21,741

-20,427

-294

13,104

12,839

768

-16,492

-4,278

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-86,868

-22,321

-14,336

-13,688

0

0

0

Financing activities
Proceeds from sale of future royalties to a related party, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of future royalties, net

0

27,618

27,618

27,618

27,618

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from common stock sales facility, net of issuance costs

-

-

-

-

-

9,330

9,330

9,355

3,408

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from issuances of common stock, net

-

-

-

-

-

289

331

314

175

146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of note payable

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on financing obligation

-

-

-

-

-

-

-

-

-

292

397

428

421

415

410

404

338

236

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuances of common stock related to stock incentive plans and awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

747

-

2,696

3,514

3,091

3,881

3,727

3,731

4,775

5,299

0

0

0

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-83

622

723

1,100

2,321

3,684

3,571

2,933

3,723

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from issuances of common stock related to stock incentive plans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Capital lease payments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash provided by financing activities

19,684

27,730

27,725

27,671

33,800

5,619

5,661

5,595

-601

-146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

169,296

53,634

51,263

50,577

0

0

0

Net increase in cash, cash equivalents and restricted cash

-22,147

-26,041

-10,313

-6,225

22,372

14,009

-1,364

-17,547

-45,884

-41,135

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-114,110

-38,777

-12,256

-109,290

-119,235

-183,973

49,091

168,074

239,291

267,779

30,268

-46,171

-107,628

561

35,597

77,680

151,545

29,826

2,189

1,742

3,780

0

0

0

Supplemental schedule of noncash activities
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

1,211

1,218

1,225

1,231

1,238

1,030

721

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental schedule of noncash activities
Loan commitment asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,850

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Facility fee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,350

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-201

65

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for repayment of note payable, including interest

-

-

-

-

-

2,301

2,301

2,301

2,301

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for compensation

444

0

0

0

0

493

493

493

493

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in property and equipment for amount paid by landlord

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,059

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-